6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04887467 (ClinicalTrials.gov)	September 16, 2021	26/4/2021	Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease	Pharmacokinetic Study of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease Under Stabilized Treatment.	Parkinson Disease	Drug: Apomorphine	Rennes University Hospital	NULL	Recruiting	50 Years	70 Years	Male	20	Phase 4	France
2	EUCTR2016-000102-11-NL (EUCTR)	23/11/2016	08/11/2016	Trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations.	Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations. - Apomorphine in PD patients with visual hallucinations: a RCT	Parkinson's disease patients with refractory visual hallucinations MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: APO-go Product Name: Apomorphine	University Medical Center Groningen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2;Phase 3	Netherlands
3	NCT02339064 (ClinicalTrials.gov)	February 2015	31/3/2014	Infusion of Apomorphine: Long-term Safety Study	A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy	Idiopathic Parkinson's Disease	Drug: apomorphine infusion	US WorldMeds LLC	NULL	Active, not recruiting	30 Years	N/A	All	99	Phase 3	United States
4	NCT01039090 (ClinicalTrials.gov)	February 2009	22/12/2009	Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease	Prospective, Randomised, Comparative Study Comparing Efficacy of Continuous Apomorphine Infusion Versus Usual Dopaminergic Per os Treatment on Cognitive and Neuropsychological Functions in Parkinson's Disease: a Clinical and PET-scan Study	Parkinsons's Disease	Drug: Continuous Apomorphine infusion;Drug: Usual dopaminergic per os treatment	Rennes University Hospital	NULL	Completed	18 Years	N/A	All	21	Phase 3	France